Mesa Laboratories, Inc. (MLAB)
| Market Cap | 572.87M -9.5% |
| Revenue (ttm) | 247.54M +4.1% |
| Net Income | 3.73M |
| EPS | 0.68 |
| Shares Out | 5.52M |
| PE Ratio | 152.43 |
| Forward PE | 74.77 |
| Dividend | $0.64 (0.62%) |
| Ex-Dividend Date | May 29, 2026 |
| Volume | 78,387 |
| Open | 102.88 |
| Previous Close | 102.89 |
| Day's Range | 101.02 - 104.10 |
| 52-Week Range | 55.45 - 131.20 |
| Beta | 0.94 |
| Analysts | Hold |
| Price Target | 94.00 (-9.35%) |
| Earnings Date | May 27, 2026 |
About MLAB
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the denta... [Read more]
Financial Performance
In fiscal year 2025, Mesa Laboratories's revenue was $240.98 million, an increase of 11.47% compared to the previous year's $216.19 million. Losses were -$1.97 million, -99.22% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for MLAB stock is "Hold" and the 12-month stock price target is $94.0.
News
Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
LAKEWOOD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ended March 31, 202...
Mesa Labs CEO Gary Owens to step down, Siddhartha Kadia to succeed
Mesa Labs (MLAB) announced that Gary Owens will step down as president and CEO on April 12 and will enable a leadership transition. To lead the company’s next chapter, the…
Mesa Labs price target raised to $94 from $83 at Wells Fargo
Wells Fargo raised the firm’s price target on Mesa Labs (MLAB) to $94 from $83 and keeps an Equal Weight rating on the shares. The firm notes the company posted…
Mesa Laboratories Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company highlighted its strong recurring revenue base, disciplined growth through both organic initiatives and strategic acquisitions, and resilience amid recent market headwinds. With a focus on regulated markets and continuous operational improvement, it expects accelerating growth as clinical trial activity rebounds.
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quart...
Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, to...
Mesa Labs price target raised to $83 from $75 at Wells Fargo
Wells Fargo raised the firm’s price target on Mesa Labs (MLAB) to $83 from $75 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on…
Mesa Laboratories Transcript: Jefferies London Healthcare Conference 2025
Biopharmaceutical development and calibration solutions showed strong growth, with regional disparities in clinical genomics due to China headwinds. Cost reductions and reinvestments are supporting commercialization and operational improvements, while M&A and APAC expansion remain strategic priorities.
Mesa Laboratories, Inc. to Participate in Upcoming Investor Conferences
LAKEWOOD, Colo., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that Gary Owens, President and CEO, and John Sakys, CFO will be attending the following upcomin...
Mesa Labs price target raised to $115 from $110 at Jefferies
Jefferies analyst Tycho Peterson raised the firm’s price target on Mesa Labs (MLAB) to $115 from $110 and keeps a Buy rating on the shares following a Q2 report that…
Mesa Laboratories, Inc. to Announce Second Quarter Results on November 6, 2025
LAKEWOOD, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the second quarter of fiscal year 2026 following market c...
Mesa Laboratories Executes Previously-Announced Strategic Financing Plan
LAKEWOOD, Colo., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, “Mesa” or the “Company”) today announced that it has executed on its previously-announced financ...
Mesa Labs upgraded to Equal Weight from Underweight at Wells Fargo
Wells Fargo upgraded Mesa Labs (MLAB) to Equal Weight from Underweight with a price target of $67, down from $100. The firm believes the recent sharp stock selloff appears overdone…
Mesa Labs Announces First Quarter Results
LAKEWOOD, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, to...
Mesa Laboratories, Inc. to Announce First Quarter Results on August 5, 2025
LAKEWOOD, Colo., July 02, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the first quarter of fiscal year 2026 at approximately 8:...
Mesa Labs price target lowered to $100 from $120 at Wells Fargo
Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Mesa Labs (MLAB) to $100 from $120 and keeps an Underweight rating on the shares. The firm notes Q4…
Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2025 Results
LAKEWOOD, Colo., May 28, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, tod...
Mesa Labs Announces Third Quarter Results
LAKEWOOD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, to...
Mesa Laboratories, Inc. to Announce Third Quarter Results on February 4, 2025
LAKEWOOD, Colo., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2025 at approximately 8:...
Mesa Labs price target lowered to $150 from $160 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Mesa Labs (MLAB) to $150 from $160 and keeps an Outperform rating on the shares. Mesa reported “mixed” fiscal…
Mesa Labs Announces Second Quarter Results
LAKEWOOD, Colo., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, to...
Mesa Labs target raised, added to ‘Tactical Outperform’ list at Evercore ISI
Evercore ISI raised the firm’s price target on Mesa Labs (MLAB) to $160 from $120 and keeps an Outperform rating on the shares. In MedTech, utilization remains positive into Q3…
Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results
LAKEWOOD, Colo., June 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, to...
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results
LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2...
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results to May 31, 2024
LAKEWOOD, Colo., May 22, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending Ma...